Xtant Medical Holdings, Inc Q2 Earnings Summary

Written by Emily J. Thompson, Senior Investment Analyst

Source: NASDAQ.COM

Updated: Aug 12 2025

0mins

XTNT+1.46%

Should l Buy XTNT?

Source: NASDAQ.COM

Earnings Performance: Xtant Medical Holdings, Inc reported earnings of $3.55 million in Q2, a significant improvement from a loss of $3.86 million in the same period last year, with an EPS of $0.02 compared to -$0.03 previously.
Revenue Growth and Guidance: The company achieved revenue of $35.41 million in Q2, up from $29.94 million year-over-year, and provided full-year revenue guidance of $131 - $135 million.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy XTNT?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on XTNT

Wall Street analysts forecast XTNT stock price to rise

2 Analyst Rating

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.618

Low

1.50

Averages

1.50

High

1.50

Current: 0.618

Low

1.50

Averages

1.50

High

1.50

BTIG

Buy

downgrade

2025-11-11

Reason

BTIG

Price Target

AI Analysis

2025-11-11

downgrade

Buy

Reason

BTIG lowered the firm's price target on Xtant Medical to $1.50 from $2 and keeps a Buy rating on the shares. Xtant Medical reported Q3 revenue up 19% year over year and EPS of 1c, slightly above estimates, driven by $5.5M in license revenue, the analyst tells investors in a research note. The company reaffirmed FY25 guidance of $131M-$135M and appears positioned for self-sustained growth, with high single-digit expansion expected in FY26 and beyond, BTIG says.

About XTNT

Xtant Medical Holdings, Inc. is a global medical technology company. The Company is focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. Its biomaterial products include OsteoSponge, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, OsteoVive, OsteoFactor, line of 3Demin products, as well as other allografts. It offers a comprehensive line of products that are used to treat a variety of spinal and sacroiliac conditions, including trauma, degeneration, deformity and tumor. Its key spinal implant product lines include Cervical products, Thoracolumbar products, Sacroiliac Joint products, and Interbody products.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Xtant Medical Launches Next-Gen nanOss Strata™ Synthetic Bone Graft

Dec 11 2025PRnewswire

Product Innovation: Xtant Medical has launched nanOss Strata™, a synthetic bone graft made from hydroxycarbonapatite (HCA) with higher solubility than traditional materials, aimed at enhancing bioactivity and improving integration with surrounding bone tissue during healing.
Market Availability: Strata™ is now accessible through Xtant Medical's nationwide distribution network, marking the company's ongoing commitment to innovation in regenerative medicine and aiming to assist surgeons in improving patient surgical outcomes.
Diverse Product Forms: The product is available in compression-resistant preformed strips and prehydrated moldable grafts, both of which are sterile and highly moldable, allowing for rapid absorption of blood and other biological fluids to meet various surgical needs.
Strategic Goals: By introducing Strata™, Xtant Medical further solidifies its position in the orthopedic and spinal surgical solutions market, which is expected to drive future revenue growth and enhance market share.

Companion Spine Acquires Paradigm Spine, Expanding Spine Implant Market Reach

Dec 01 2025Businesswire

Acquisition Completed: Companion Spine has finalized its acquisition of Paradigm Spine, integrating the Coflex® and CoFix® implants, which is expected to enhance its competitive edge in the spine implant market and increase market share to meet global demand.
Leadership Integration: The new company will be led by Anthony G. Viscogliosi as Executive Chairman and CEO, with Enrico Sangiorgio as Executive Vice President International, ensuring stability in leadership and capability for market expansion.
Expanded Product Portfolio: The combined product offerings include various spinal stabilization solutions that cater to a range of conditions, which is anticipated to improve customer satisfaction and strengthen partnerships with distributors.
Market Strategy Overhaul: Companion Spine will focus on the U.S. market, leveraging its FDA-approved product portfolio to enhance physician awareness of SMART™ technologies, thereby optimizing patient treatment outcomes and driving long-term growth for the company.

Xtant Medical Sells Non-Core Assets for $19.2 Million

Dec 01 2025Newsfilter

Asset Sale: Xtant Medical has completed the sale of its Coflex® spinal implant assets and all OUS entities of Paradigm Spine GmbH to Companion Spine for approximately $19.2 million, consisting of $11 million in cash and $8.2 million in short-term seller financing, which is expected to enhance the company's financial liquidity.
Debt Reduction: The net proceeds from this transaction will be used to reduce long-term debt, enabling Xtant Medical to continue operations without the need for additional external capital, thereby strengthening the company's financial stability.
Focus on Core Business: CEO Sean Browne stated that this asset sale represents a significant step in allowing the company to concentrate on its core biologics business, driving innovation and improving financial performance, reflecting the company's commitment to strategic transformation.
Operational Contribution: The operating contributions of these assets and entities will be included in the company's results through the December 1, 2025 date of sale, indicating the company's continued valuation of these businesses prior to the sale.